 CAMBRIDGE, Mass. BEIJING--BUSINESS WIRE--- BGNE BTKi--BeiGene, Ltd. NASDAQ: BGNE; HKEX: 06160, a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that BRUKINSA zanubrutinib has been approved by Health Canada for the treatment of mantle cell lymphoma MCL in adult patients who have received at least one prior therapy. This is the second approval for BRUKINSA in Cana 